Skip to main content
Clinical Trials/NCT02421406
NCT02421406
Completed
Not Applicable

An Internet-based Behavioral Weight Loss Program for HIV+ Patients

The Miriam Hospital0 sites50 target enrollmentMay 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Overweight
Sponsor
The Miriam Hospital
Enrollment
50
Primary Endpoint
Weight
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The goal of this project is to determine whether an Internet-based weight loss program will lead to weight loss and improvements in cardiovascular disease risk factors in people living with HIV.

Detailed Description

The goal of this project is to provide an empirically validated weight loss program to HIV+ patients and evaluate its efficacy for weight loss and improvements in cardiovascular disease risk factors. Investigators will conduct a randomized pilot study with 50 overweight or obese patients who are HIV+, are recruited from the Miriam Hospital Immunology Center, and are interested in losing weight. These patients will be randomly assigned to a 12 week behavioral weight loss program delivered via the Internet or to a 12 week education only control group (also Internet based). Primary aims of this study are 1) to determine whether an Internet program is appropriate for this patient population, assessed by the success of recruiting 50 patients for the trial and their level of adherence over the 12 weeks, 2) to compare weight losses at the end of the 12 week program for program for patients randomized to the Internet behavioral weight reduction program (WT LOSS) relative to the Internet education program (CONTROL), 3) to compare the efficacy of the WT LOSS program relative to CONTROL for improving lipids (total cholesterol, HDL, LDL, triglycerides), metabolic measures (fasting blood sugar, insulin), and inflammatory markers (IL-6, C-reactive protein, adiponectin), and 4) to compare the changes in dietary intake and physical activity from baseline to 12 weeks in the WT LOSS and CONTROL conditions. Investigators will also store blood for later analysis of other adipokines (leptin) and biomarkers of microbial gut translocation (e.g., sCD14). These will provide important pilot data for future NIH funding related to both the implementation of weight loss programs and the effect of weight loss on the co-morbidities in this population.

Registry
clinicaltrials.gov
Start Date
May 2015
End Date
February 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Recruited from the Miriam Hospital Immunology Center
  • HIV+ with a CD4 count \>200 and an undetectable viral load
  • BMI greater than 27 kg/m2
  • No health problems that make weight loss or unsupervised exercise unsafe
  • English speaking
  • Have access to a computer and the Internet

Exclusion Criteria

  • Report a heart condition, chest pain during periods of activity or rest, or loss of consciousness on the Physical Activity Readiness Questionnaire
  • Active substance abuser
  • Currently pregnant or intend to become pregnant in the next 6 months
  • Planning to move outside of the state within the next 6 months
  • Have participated in a study conducted by the Weight Control \& Diabetes Research Center in the past 2 years

Outcomes

Primary Outcomes

Weight

Time Frame: 12 weeks

Secondary Outcomes

  • Physical activity assessed by objective monitoring of activity(12 weeks)
  • Lipid profile assessed by analysis of fasting blood work(12 weeks)
  • Diet assessed by 24-hour recalls(12 weeks)
  • Inflammatory profile assessed by analysis of fasting blood work(12 weeks)
  • Metabolic profile assessed by analysis of fasting blood work(12 weeks)

Similar Trials